Development and Characterization of Lipid Nanocarriers for Vancomycin HCL Delivery: A Comparative Study of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC)

Abstract

Background and Objectives For improved oral drug administration, this work explores the creation and assessment of vancomycin-loaded lipid nanocarriers, such as Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC). In order to evaluate the formulations' potential for drug integration, encapsulation efficiency (EE) and loading capacity (LC) were measured after hot homogenisation and ultrasonication.

Methods To assess the stability of the blank and vancomycin-loaded formulations, measurements were made of their particle size, zeta potential, and polydispersity index (PDI). Vancomycin release patterns were assessed by in vitro release experiments carried out in an enzyme-free artificial intestinal environment. Compared to SLN, NLC showed a more regulated and prolonged release, holding onto a greater release percentage throughout time.

Results The process of lyophilization led to a marginal increase in particle size, but the drug-encapsulating qualities of both nanocarriers were retained. ANOVA statistical analysis verified the significance of variations in the formulations' release behaviours (P < 0.05). The results imply that because of its enhanced encapsulation and prolonged release profile, NLC may provide vancomycin administration with higher bioavailability and therapeutic effectiveness.

Conclusions This work demonstrates how lipid-based nanocarriers may be used to create efficient oral delivery systems for medications like vancomycin.